October 15, 2018Download pdf
Bresso (MI), Italy – October 15, 2018 - EryDel SpA (www.erydel.com), a biotech company specializing in the development and commercialization of drugs and diagnostics delivered through autologous red blood cells, today announced the appointment of Ronan W. Gannon as Chief Commercial Officer, effective immediately.
“I am pleased to welcome Ronan to EryDel,” said Dr. Luca Benatti, Chief Executive Officer of EryDel. Ronan’s commercial expertise in rare diseases and blood products will be critical as we advance our comprehensive development program for EryDex, including our pivotal Phase 3 clinical study (ATTeST) in Ataxia Telangiectasia and seek to transition EryDel from a late-stage research and development company to a commercial-stage organization. We look forward to his contribution as a member of our leadership team.”
Ronan brings more than 25 years of industry experience across large, midsize and startup life science companies. Before joining EryDel, Ronan led global commercial operations at Radius Health, where he helped transform the company from a late-stage development startup into a fully integrated biopharmaceutical company. Prior to that, Ronan spent ten years at CSL Behring where he held several leadership roles including US Vice President Marketing and North America general management roles in the US and Canada. During his tenure at CSL Behring he launched six orphan drugs. Prior to CSL, Ronan led sales and marketing teams at Zeneca Pharmaceuticals, and GlaxoSmithKline across several therapeutic areas including biologicals, oncology, and asthma. He received an MBA from Northeastern University, a BA from the University of Richmond and holds alumni status from the Harvard Business School.
"I am delighted to join EryDel as the company begins planning for the commercialization of EryDex,“ said Mr. Gannon. “EryDel has played a significant role in developing an innovative treatment for Ataxia Telangiectasia, a life-threatening disease. I look forward to working with the team to continue ongoing community and market development efforts, and to advance a robust commercialization strategy for the launch of EryDex.”
About Ataxia Telangiectasia
Ataxia Telangiectasia (AT) is a rare genetic disease caused by biallelic mutations in the ataxia telangiectasia mutated (ATM) gene, for which no established therapy is currently available. ATM encodes a PI3Kinase protein shown to play a pivotal role in response to DNA damage and cell cycle control. Homozygosity for ATM mutations result in a multi-systemic disorder, involving mainly the nervous and immune systems. The major clinical feature of AT is severe progressive neurodegeneration from early infancy. Specific features include progressive ataxia of the trunk and limbs, involuntary movements, oculomotor apraxia, difficulties with speech and swallowing, and delayed peripheral neuropathy. Other clinical features of patients with the classical phenotype include oculocutaneous telangiectasia, immunodeficiency with recurrent respiratory tract infections, radiosensitivity and an increased incidence of cancer.
EryDel SpA is a biotechnology company specialized in the development of drugs delivered through red blood cells (RBCs) by using a proprietary medical device technology. Its most advanced product, EryDex System (EDS) is under late stage development for the treatment of Ataxia Telangiectasia, a rare autosomal recessive disorder for which no established therapy is currently available. EryDex has received Orphan Drug designation for the treatment of AT both from the FDA and the EMA. A completed pilot Phase II trial in AT patients demonstrated statistically significant efficacy of EDS on both the primary and secondary efficacy measures. An international multi-center, Phase III pivotal study, ATTeST, is being conducted. EryDel has a pipeline of preclinical programs that use its proprietary RBC’s delivery technology for the treatment of other rare diseases.
The ATTeST project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 667946”.
Media contact: Emanuela Germi at +39 02 36504470 or email@example.com